Jie Shen
- Oncology top 10%
- Cancer Immunotherapy and Biomarkers 9
- Cancer Cells and Metastasis 5
- Colorectal Cancer Treatments and Studies 5
- Immunology top 10%
- Immunotherapy and Immune Responses 5
-
- Cancer Genomics and Diagnostics 5
-
- Gastric Cancer Management and Outcomes 5
-
- Cholangiocarcinoma and Gallbladder Cancer Studies 7
-
- Hepatocellular Carcinoma Treatment and Prognosis 6
- Cited by
- OncologyImmunologyCancer Research
- Partner nations
- ChinaUnited StatesGermany
In The Last Decade
Jie Shen
62 papers receiving 885 citations
Peers
Comparison fields: 5 of 88
- Oncology 443
- Immunology 239
- Cancer Research 154
- Pulmonary and Respiratory Medicine 203
- Surgery 187
Countries citing papers authored by Jie Shen
This map shows the geographic impact of Jie Shen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jie Shen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jie Shen more than expected).
Fields of papers citing papers by Jie Shen
This network shows the impact of papers produced by Jie Shen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jie Shen. The network helps show where Jie Shen may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Jie Shen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 13 | |
| 2 | 2025 | 1 | |
| 3 | 2024 | 0 | |
| 4 | 2024 | 2 | |
| 5 | 2024 | 4 | |
| 6 | 2023 | 5 | |
| 7 | 2021 | 1 | |
| 8 | 2021 | 11 | |
| 9 | 2020 | 2 | |
| 10 | 2020 | 1 | |
| 11 | 2019 | 223 | |
| 12 | 2019 | 20 | |
| 13 | 2018 | 2 | |
| 14 | 2018 | 3 | |
| 15 | Capn4 induces human renal cancer cell proliferation by activating NF-κB signaling pathway through FAK phosphorylation. | 2017 | 2 |
| 16 | 2017 | 12 | |
| 17 | 2016 | 38 | |
| 18 | 2016 | 25 | |
| 19 | 2015 | 8 | |
| 20 | 2012 | 15 |
About Jie Shen
Jie Shen is a scholar working on Oncology, Cancer Research and Hepatology, having authored 65 papers that have together received 902 indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (9 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (7 papers), Hepatocellular Carcinoma Treatment and Prognosis (6 papers), Cancer Cells and Metastasis (5 papers), Immunotherapy and Immune Responses (5 papers), Cancer Genomics and Diagnostics (5 papers), Gastric Cancer Management and Outcomes (5 papers) and Colorectal Cancer Treatments and Studies (5 papers). The work is most often cited by research in Oncology (443 citations), Immunology (239 citations) and Cancer Research (154 citations). Jie Shen has collaborated with scholars based in China, United States and Germany. Frequent co-authors include Qin Liu, Baorui Liu, Huifang Su, Yan Lü, Pingping Shen, Weijie Zhang, Yuncheng Bei, Ling Liu, Wei Zheng and Wenlong Zhang.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.